share_log

Walgreens Boots Alliance | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Walgreens Boots Alliance Holdings LLC(13.2%),WBA Investments, Inc.(13.2%), etc.

SEC announcement ·  Feb 9 09:22
Summary by Moomoo AI
On February 7, 2024, Walgreens Boots Alliance Holdings LLC (WBA Holdings), a subsidiary of Walgreens Boots Alliance, Inc. (WBA), sold a significant portion of its shares in Cencora, Inc. The transaction involved the sale of 4 million shares in an unregistered block trade under Rule 144 of the Securities Act of 1933, representing approximately 13.2% of Cencora's outstanding common stock. Concurrently, WBA Holdings and Cencora entered into a share repurchase agreement, where Cencora repurchased 212,395 shares from WBA Holdings at the same price per share as the block trade. The proceeds from these transactions are intended for WBA to pay down debt and for general corporate purposes, aligning with WBA's strategy to optimize its capital efficiency within its retail pharmacy framework. This move is part of WBA's ongoing review of its strategic and capital allocation priorities, which may lead to further sales of Cencora stock. The transactions were completed with the legal counsel of Cleary Gottlieb Steen & Hamilton LLP and Morgan, Lewis & Bockius LLP.
On February 7, 2024, Walgreens Boots Alliance Holdings LLC (WBA Holdings), a subsidiary of Walgreens Boots Alliance, Inc. (WBA), sold a significant portion of its shares in Cencora, Inc. The transaction involved the sale of 4 million shares in an unregistered block trade under Rule 144 of the Securities Act of 1933, representing approximately 13.2% of Cencora's outstanding common stock. Concurrently, WBA Holdings and Cencora entered into a share repurchase agreement, where Cencora repurchased 212,395 shares from WBA Holdings at the same price per share as the block trade. The proceeds from these transactions are intended for WBA to pay down debt and for general corporate purposes, aligning with WBA's strategy to optimize its capital efficiency within its retail pharmacy framework. This move is part of WBA's ongoing review of its strategic and capital allocation priorities, which may lead to further sales of Cencora stock. The transactions were completed with the legal counsel of Cleary Gottlieb Steen & Hamilton LLP and Morgan, Lewis & Bockius LLP.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more